



PRESS RELEASE

February 12, 2024

Ziccums CEO Ann Gidner in Fireside Chat on mRNA development hosted by US Force Family Office

Based on the growing reputation that Ziccum is building in the international pharmaceutical industry, Ziccum CEO Ann Gidner has taken part in a recorded Fireside Chat reviewing the mRNA arena, its tremendous growth, and the shortcomings of the RNA/LNP technology which can be addressed by treatment with the Ziccum technology LaminarPace.

The discussion included the valuable participation of Dr Romain Micol, CEO and co-founder of Combined Therapeutics; a privately held Boston-based biotechnology company developing the next generation of high value mRNA vaccines. Dr Micol shared his insights in the field and his appreciation for the LaminarPace technology, as a Key Opinion Leader for mRNA development.

The event was hosted by Force Family Office, in the *Force for Knowledge* series, where participants across the world can learn about emerging technologies, companies and sectors, and was moderated by Steven Saltzstein, CEO of Force.

To access the recorded Fireside chat, please see link: <https://www.youtube.com/watch?v=vWiWIGMEvM4>

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is
Carnegie Investment Bank AB (publ).
Follow us on <https://eucaps.com/ziccum>

About Ziccum

Ziccum is developing LaminarPace™, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace™ uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

[Ziccums CEO Ann Gidner in Fireside Chat on mRNA development hosted by US Force Family Office](#)